TRPC6 and cardiomyopathy: In order to determine whether inhibition of TRPC6 with the peptide GsMTx-4 could prevent cardiomyopathy induced by doxorubicin in an animal model, we injected wild type B6.129 male mice with 6 doses of 4 mg/kg doxorubicin or saline/DMSO control intraperitoneally (ip) on days 1, 3, 5, 8, 10, 12 (cumulative dose of 24 mg/kg), and performed echocardiography at day 21 to determine cardiomyopathy and histology to measure cardiac fibrosis.